Many economic analyses of immunization programmes focus on the benefits
in terms of public-sector cost savings, but do not incorporate
estimates of the private cost savings that individuals receive from
vaccination. This paper considers the implications of Bahl et al.'s
cost-of-illness estimates for typhoid immunization policy by examining
how community-level incidence estimates and information on distribution
of costs of illness among patients and the public-health sector can be
used in the economic analysis of vaccination-programme options. The
findings illustrate why typhoid vaccination programmes may often appear
to be unattractive to public-health officials who adopt a public
budgetary perspective. Under many plausible sets of assumptions,
public-sector expenditure on typhoid vaccination does not yield
comparable public-sector cost savings. If public-health officials adopt
a societal perspective on the economic benefits of vaccination, there
are many situations in which different vaccination programmes will make
economic sense. The findings show that this is especially true when
public decision-makers recognize that (a) the incidence of typhoid
fever is underestimated by blood culture-positive cases and (b) avoided
costs of illness represent a significant underestimate of the actual
economic benefits to individuals of vaccination